Long term human study proves Nicotinamide Riboside safely elevates NAD+

two-anti-aging-drugs
Preliminary results are in for this clinical study of 120 elderly subjects taking Elysium Health’s BASIS that was completed July 28.

Although the full results are not yet published, Elysium Health just issued this press release stating that primary and secondary endpoints were met.

Healthy patients between 60 and 80 years of age were given placebo,  or 2 different dosages of BASIS daily for 8 weeks.

BASIS is a combination of 2 products patented by Chromadex , Nicotinamide Riboside (NR) and Pterostilbene.

Note – this is not the same as NMN (Nicotinamide Mono-Nucleotide).

Those given BASIS received either a single capsule containing 250 mg Nicotinamide Riboside (NR), and 50 mg Pterostilbene, or 2 capsules, containing 500 mg NR and 100 mg Pterostilbene.

The full study can be found here:

A Study to Evaluate Safety and Health Benefits of Basis™ Among Elderly Subjects

Some of the findings noted in the press release were:

  • Study subjects showed no serious adverse events, confirming BASIS to be safe for use over extended periods
  • Subjects taking a single capsule with 250mg NR showed an average increase in blood NAD+ levels of 40% over baseline by week 4 and maintained that increase throughout the trial
  • Subjects taking 2 capsule with 500mg NR were found to have a 90% elevation in blood NAD+ levels at week 4, and maintained a significantly higher blood NAD+ level throughout the trial (compared to those taking a single capsule)
Long term supplementation with NR is safe and effectively elevates NAD+ levels in Humans

RESULTS – DOSAGE IMPLICATIONS

dosageA previously published human study on NR supplemention effects on NAD+ levels used 100, 300, and 1,000mg dosages of NR.

Results from the 2 experiments in that prior study seemed to indicate the most effective dosage of NR as being somewhere between the 300 and 1,000mg levels.

Although details are scarce, the preliminary results from this most recent clinical study seem to agree with the prior study as to NR dosage effects on blood NAD+.

We note the press release says the higher dosage with 500mg of NR showed 90% increase in NAD+ over baseline at 4 weeks.

That 90% increase was not maintained throughout, but did show a “significant increase” throughout the study.

So, the blood NAD+ increase was higher at 4 weeks and came back down somewhat over the remaining 4 weeks the study. (testing was limited to 4 times throughout the study)

This seems to indicate that the maximum sustainable NAD+ increase thru NR supplementation is achieved with 500 mg a day, and any dosage higher than 500mg would probably not be more effective.

It’s quite possible that a dose lower than 500 mg that would achieve same increase in NAD+, but there is no clue from this study what that dose might be.

Note that these are averages and that individuals exhibit a wide variety of response to NR supplementation.

On average, 500 mg day of NR appears to be sufficient to achieve maximum blood NAD+ elevation

WHAT WE RECOMMEND

STUDY DESIGN

Some things we find interesting about the study design:

  • Dosages of 250 and 500mg only. Implies they don’t believe more than 500mg is beneficial
  • Only 4 office visits during the testing, so not going to see daily NAD+ levels

Primary Outcomes

  • Basic health parameters to ensure safety – blood pressure, blood parameters, heart rate.  Should be no problem at these dosages, so expect press release soon saying they met primary endpoints

Secondary Outcomes

  • NAD+ measurements as expected
  • Interesting they include a lot of performance measurements – treadmill, chair standing, elderly activity testing.
  • Body Weight measurement – weight loss has been mentioned in some reports, but very little so far.  Could be a game changer if positive response

Other

  • Pain Assessment.  Another benefit that has been mentioned very little in previous reports

Inclusion/Exclusion Criteria

  • Healthy individuals only
  • 60 to 80 years age – much older than the first study published on human testing.  Will be very interesting to see dosage and NAD+ response in this population
  • Bodyweight – 18-35kg per m2 – fairly limited upper weight is surprising – maybe limiting the potential for weight loss.

 

Primary Outcome Measures:

 

Secondary:

screen-shot-2016-10-17-at-3-00-35-pm

Other:

screen-shot-2016-10-17-at-2-48-00-pm

Exclusion

screen-shot-2016-10-17-at-2-48-33-pm

Inclusion:
screen-shot-2016-10-17-at-2-48-18-pm